Catch up on Healio’s top five items in ophthalmic business from May.
Hot topics include de novo authorization for an AI-powered remote OCT device, FDA approvals for aflibercept biosimilars and Merck’s acquisition of EyeBio.
Merck to acquire EyeBio
Restoret, EyeBio’s lead candidate for diabetic macular edema and wet age-related macular degeneration, is part of the acquisition, which is potentially valued at $3 billion. Read more.
Bausch + Lomb receives Canadian approval for enVista Envy IOL
A decision from the FDA on U.S. approval is expected later this year. Read more.
FDA